Articles related to TRIPLE-NEGATIVE BREAST CANCER (TNBC)

Phase 3 ASCENT-04 data presented at ASCO 2026 showed improved PFS2 for sacituzumab govitecan plus pembrolizumab over chemotherapy plus pembrolizumab in previously untreated PD-L1-positive advanced triple-negative breast cancer, though an independent expert challenged PFS2 as a valid endpoint for establishing frontline standard-of-care status.

Melittin, a peptide in bee venom, disrupted cancer cell membranes in preclinical animal and laboratory models, with triple-negative breast cancer cells showing particular susceptibility.

Castalin can boost the effectiveness of CHK1 inhibitors, a class of drugs currently in phase 1 clinical trials. When tested in cellular models of triple-negative breast cancer, one of the most aggressive forms of the disease, Castalin was shown to enhance the action of these inhibitors.

Explore the detailed findings of a recent study that highlights the impact of treatment interruptions on survival rates in triple-negative breast cancer patients undergoing adjuvant radiotherapy.

Unfolding the Potentials of Anti-TROP2 ADC Therapy in Triple-Negative Breast Cancer Evolving therapeutic paradigms for triple-negative breast cancer (TNBC) are in focus, as esteemed experts highlight the use of novel anti-TROP2 antibody drug conjugates in an enlightening multidisciplinary tumor board.

There were significant state variations in racial and ethnic disparities in TNBC incidence in this cohort study, with Black women in Delaware, Missouri, Louisiana, and Mississippi having the highest rates among all states and racial and ethnic populations. More research is needed to identify factors contributing to the significant geographic variations in racial and ethnic disparities in TNBC incidence in order to develop effective preventive measures, and social determinants of health contribute to the geographic disparities in TNBC risk, according to the findings.